It is critical that frontline line workers receive access to effective mental health treatment to support their ability to remain engaged and effective in their work." The pandemic continues to destabilize and impact so many people and especially those in helping professions. Robison continued: "It has been an incredible experience to see how this treatment is helping individuals who play such an important role in taking care of the health of our communities. "Even when I do feel myself reacting, I feel I have more awareness and I am able to better regulate."ĭr. I feel less ‘hooked' by things that used to hook me into responses," said another patient. "The greatest improvement has been my PTSD.
There were many fears of abandonment when I first entered the study and by the end, this has immensely improved." One patient from the pilot investigation commented, "I feel an overall sense of forgiveness and sense of security in who I am and my future. Following a complementary screening process, groups of up to six individuals are selected to participate in a six-week protocol that includes group psychotherapy, integration sessions and three ketamine dosing sessions co-led by a licensed psychotherapist and a licensed prescriber. "With each cohort, we found positive results treating frontline healthcare workers experiencing symptoms of burnout, PTSD, depression, and anxiety using group KAP, in combination with integration sessions, on a weekly basis."įrontline KAP is currently being offered at Novamind's Murray Clinic, one of several clinics in its network purposefully designed to accommodate group treatment. "We're thrilled to expand the Frontline KAP service offering after the success we saw throughout the pilot," said Dr. The expanded treatment program now also welcomes individuals in demanding helping professions such as police, firefighters and paramedics who experience similar work-related stressors. 1 Frontline KAP provides a platform for processing trauma with peers, more effectively building community and reducing feelings of isolation compared to individual treatment. Healthcare workers are significantly impacted by the pandemic with reports of 93% experiencing stress, 86% experiencing anxiety and 76% experiencing exhaustion and burnout.
Novamind, in partnership with Wholeness Center, piloted the program over a nine-month period to investigate group ketamine-assisted psychotherapy (KAP) for frontline healthcare workers suffering from pandemic-related burnout, stress and trauma. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, today strengthens its clinical programming with the announcement that Frontline KAP, a group-based psychedelic treatment program, is now accessible to the public at select Novamind clinics. TORONTO, ON / ACCESSWIRE / / Novamind Inc. They also will probably have much less dilution moving forward since they're going more slow and steady with clinical expansion unlike NUMI.Following successful clinical pilot, treatment becomes regular offering at Novamind clinics I personally believe in NM for highest ROI due to their current revenue stream of psychedelic therapies and don't anticipate them having difficulty extending into other psychedelics. At the end of the day who can administer these technologies won't likely be too red taped, and it'll be who can work with insurance to bring the widest variety of patients into their facility with a patient friendly experience. MAPS also said they don't plan on being exclusive with any clinic. They seem to be more geared toward rapid expansion of clinics and being the first to administer therapies.Įach will likely be a successful company but imo Numis main advantage point is their relationships with MAPS and HC that let them be the first to do these therapies. They have great relationships with MAPS and Health Canada which set them at the forefront of administering these treatments when they are publicly available. Numi on the other hand has a significantly higher market cap and less revenue but more cash on hand raised and plans for expansion. One of their more undervalued components imo is their investment in ATAI and partnership with multiple major pharma companies like Merck and Janssen for clinical trials. They plan to incorporate treatments with psilocybin and MDMA in the next few years when it is available.
They have significant existing revenue in relation to their market cap and primarily administer ketamine treatments with facilities growing. NM is established with consistent revenue and likely is a "safer" option (noting its still a very speculative space). Imo one of the largest differences in NM and NUMI is the rate of growth they're aiming for.
0 kommentar(er)
